top of page
ARTICLES
Explore published articles and webinars from Litmys leaders that spotlight new thinking and practical approaches to achieving market success across the life sciences.
Managing Partner, Harris Kaplan, joins industry experts in FirstWord ExpertViews: The Future Impact of the Inflation Reduction Act on Pharma Drug Pricing
The decisions that shape commercial success are increasingly being made long before launch. As the Inflation Reduction Act continues to influence pricing, access, and reimbursement dynamics, companies must consider how evidence generation, differentiation, and value communication fit into their development strategy from the outset. In FirstWord's ExpertViews report, The Future Impact of the Inflation Reduction Act on Pharma Drug Pricing, Harris Kaplan shares his perspective a
6 days ago1 min read
Managing Partner, Harris Kaplan, published in BioSpace: Why KOL Enthusiasm Often Doesn’t Predict Commercial Success
KOL enthusiasm can signal early promise, but it rarely tells the full story. Harris Kaplan examines why expert advocacy often fails to translate into market adoption—and what life sciences teams should evaluate instead.
Apr 221 min read
Regulatory Uncertainty in Life Sciences Is Increasing the Risk of Innovation
Innovation in life sciences has always involved uncertainty. Today, however, regulatory unpredictability is becoming a growing driver of risk, influencing not only approval pathways but also real world confidence in new therapies.
Feb 181 min read
Managing Partner, Harris Kaplan, published in PharmExec: Your Phase III Clinical Protocol Is Your Initial Product Launch
Phase III clinical protocols do more than satisfy regulators. They determine what a product can claim, how it will be valued, and whether it can truly compete at launch.
Jan 301 min read
bottom of page